Research study aims to detect lung cancer earlier via simple test

PICTURED: Professors Ira Goldsmith (left) and Dean Harris are leading the research.

A simple blood test could lead to the earlier detection and treatment of lung cancer thanks to a research study in Swansea Bay.

Swansea Bay University Health Board and Swansea University are collaborating on a specific technique which aims to detect the disease more quickly, and prevent patients from undergoing invasive and unpleasant tests.

Lung cancer is the third most common cancer in the UK, with more than 43,000 people diagnosed with the condition every year.

In the UK, the long-term five-year survival of individuals diagnosed with lung cancer is 14 per cent, but when diagnosed in its early stages (Stage I and II) when the cancer is small and treatable with surgery, that rises to over 65%.

The study is being led by Professors Dean Harris and Ira Goldsmith, and governed by the health board’s research and development department with support from research delivery nurses, which are funded by Health and Care Research Wales.

More than 60 patients who have had lung nodules detected have volunteered to be part of the research by giving a simple blood test. Those results are now being analysed as part of the study.

Professor Harris said: “The outcome of this study could be hugely significant for our patients and have a massive impact on their lives.

“Early diagnosis when a suspicious nodule is detected in the imaging process is vital for the best outcome of our patients.

“Our study is hoping to detect lung cancer quicker from a blood test which can then lead to treatment getting underway sooner.”

This work comes on the back of a similar project that Professor Harris led in 2023. That saw bowel cancer patients being the first in the UK to be offered a unique blood test to make sure it has not returned.

His latest study, which is expected to run until October, uses a technique called Raman spectroscopy to detect changes in blood samples related to lung cancer.

This technique measures the interaction of laser light with cells, chemicals and molecules within the blood to create a unique ‘fingerprint’ that is predicted to be specific for lung cancer in patients who have a lung nodule detected during X-rays or CT scans that may be associated with that form of cancer.

If successful, it is expected to have a big impact on the diagnosis of lung cancer at a far earlier stage.

PICTURED: (From left) Caroline Davies, Jenny Travers and  Claire Chapman of the research and development team with Professors Ira Goldsmith (left) and Dean Harris.

The study has been made possible by funding of £45,000 by the Medical Research Council Impact Acceleration Account, which provides funding to speed up the transition from discovery research to delivering it as part of healthcare.

Professor Harris said: “Current screening tests involve CT scans which can’t always tell if nodules are cancerous, so alternative tests are needed.

“It’s very exciting to be leading on this study, particularly as it could affect so many people in our community.

Professor Goldsmith highlighted the importance of the health board’s partnership with Swansea University.

Professor Goldsmith said: “The faculty of Health and Life-Sciences at Swansea University has purpose-built, modern laboratory facilities with access to Raman Spectroscopy.

“The university also has a fantastic ethos of advancing research in life sciences by drawing on clinicians like ourselves to carry out and develop new research ideas and research projects.

“We have an excellent collaborative relationship with Swansea University, which has allowed us to take on this very important piece of research.

“With our research we hope to develop a simple blood testing technique that will allow GPs and clinicians here in Swansea Bay, Wales and around the world to help diagnose lung cancer in its very early stages with greater certainty.

“It is a blood test we hope will also become part of the lung cancer screening protocol and assist the screening program to detect and diagnose early lung cancer when it is very small with much greater accuracy.

“By doing so, more patients will be able to receive curative treatment than is currently possible.”